Compare Peptides
Select any two compounds for a side-by-side comparison of mechanism, uses, risks, and FDA regulatory status.
Popular comparisons
The first widely used GLP-1 receptor agonist for weight management, developed by Novo Nordisk. Predates semaglutide and tirzepatide. While largely superseded by newer agents for weight loss, it remains FDA-approved and widely prescribed, particularly for patients who tolerate it well or have established insurance coverage.
A non-peptide, small-molecule GLP-1 receptor agonist developed by Eli Lilly. Unlike semaglutide and tirzepatide which are peptides requiring injection, orforglipron is a fully oral pill taken once daily with no fasting requirement. Phase 3 trials are underway, potentially making it the first truly convenient oral GLP-1 option.
Activates GLP-1 receptors, stimulating insulin secretion, suppressing glucagon, slowing gastric emptying, and reducing appetite. Requires daily injection due to a shorter half-life than semaglutide. The daily dosing schedule is both a limitation and, for some patients, a feature — easier to stop quickly if side effects occur.
Activates GLP-1 receptors through a non-peptide chemical scaffold, producing the same downstream effects as injectable GLP-1 agonists — appetite suppression, insulin secretion, and slowed gastric emptying. The oral bioavailability is achieved through its small-molecule structure, unlike oral semaglutide (Rybelsus) which requires strict fasting protocols.
- Weight management (FDA-approved as Saxenda)
- Type 2 diabetes (FDA-approved as Victoza)
- Cardiovascular risk reduction
- Weight management (investigational)
- Type 2 diabetes (investigational)
- Metabolic health improvement
- Nausea and vomiting (common, especially during titration)
- Pancreatitis risk
- Gallbladder disease
- Potential thyroid C-cell tumor risk (animal data)
- Daily injection burden vs. weekly alternatives
- GI side effects (nausea, diarrhea, vomiting) — similar to injectable GLP-1s
- Still in Phase 3 trials — full safety profile not established
- Long-term cardiovascular outcomes data not yet available
- Not yet approved for any indication
FDA-approved as Victoza (type 2 diabetes, 2010) and Saxenda (weight management, 2014). The LEADER trial demonstrated cardiovascular risk reduction in diabetic patients. Largely superseded by semaglutide and tirzepatide for new prescriptions due to superior efficacy and weekly dosing, but remains a valid option with established long-term safety data.
Currently in Phase 3 clinical trials for obesity and type 2 diabetes. Phase 2 results showed ~14.7% weight loss at 36 weeks — comparable to injectable semaglutide. If approved, would be the first non-peptide oral GLP-1 agonist, removing the injection barrier for many patients. Potential approval 2026-2027.
This comparison is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional before starting any peptide therapy.